Hepatitis C symptoms are not obvious, the ALT level is low, the people generally believe that hepatitis C has little impact on human health and does not deserve attention. But in fact, the threat of hepatitis C to human health is no less than hepatitis B: 1, hepatitis C is a global epidemic, the infection rate of about 3%, about 35,000 new cases of hepatitis C each year; China’s population hepatitis C antibody positive rate of 3.2%, about 40 million people currently infected with hepatitis C virus, the infection rate increases with age. 2. The rate of chronicity of hepatitis C is high, and the incidence of cirrhosis and liver cancer is not low. Untreated hepatitis C chronicity rate of 50% to 85%; 20 years after infection, the incidence of cirrhosis in the general population 10% to 15%, children and young women 2% to 4%; middle-aged transfusion infected 20% to 30%; 30 years after infection, the incidence of liver cancer 1% to 3%; cirrhotic patients, the annual incidence of liver cancer 1% to 7%. 3. Hepatitis C is not easily detected. Most patients with hepatitis C have no obvious symptoms, and most of them do not discover the disease until cirrhosis or even liver cancer occurs; currently, the common test for hepatitis C is to detect hepatitis C antibody, but the antibody appears slowly after infection with hepatitis C virus, usually 2-6 months or even 1 year after the onset, so the disease is easily missed. 4. There is no vaccine available for hepatitis C virus, and vaccination is not possible. In summary, we must not take the dangers of hepatitis C lightly: 1. We must strengthen prevention and indeed reduce the incidence of hepatitis C virus infection. Hepatitis C virus is mainly transmitted through blood or blood product transfusion, hemodialysis, sharing of syringes for drug injection, sexual transmission, mother-to-child transmission, and medical devices that are not strictly sterilized. To reduce the incidence of hepatitis C must avoid the above-mentioned behaviors, phenomena occur. 2. Early detection of the disease is necessary. Those who have the above mentioned behaviors and phenomena or elevated aminotransferases for unknown reasons should be tested for hepatitis C antibodies as early as possible and, if necessary, for hepatitis C virus, and listen to professional advice. 3, hepatitis C patients should consciously restrain their own behavior. Combined hepatitis B virus infection, alcoholism, obesity, diabetes, hepatotoxic drugs and environmental pollutants can all contribute to the development of hepatitis C and the occurrence of liver cancer. 4, hepatitis C patients should start regular antiviral treatment as early as possible. The current standard treatment regimen for hepatitis C is a-interferon combined with ribavirin (commonly known as virazole) for 6 months to 1 year, with no other standardized treatment regimen. Pregnancy, uncontrolled psychiatric and autoimmune diseases, alcoholism, drug abuse, decompensated cirrhosis, symptomatic heart disease, granulocytes below 1000/mL, platelets below 50,000/mL, and organ transplant patients other than liver transplant patients should not be treated with interferon; pregnancy, renal failure, and patients with significant anemia (hemoglobin below 80 g/L) should not be treated with virazole.